Roche/GSK Boniva price
Executive Summary
The wholesale acquisition cost of Roche/GlaxoSmithKline's once-monthly osteoporosis agent Boniva (ibandronate) is $64.28 per tablet, comparable to the monthly cost of Merck's once-weekly Fosamax. Roche/GSK plan to launch Boniva by the end of April (1"The Pink Sheet" April 4, 2005, p. 4)...
You may also be interested in...
Roche/GSK Boniva Launch Plan Includes Reminders For Once-Monthly Dose
Roche and GlaxoSmithKline will support the launch of the osteoporosis therapy Boniva (ibandronate) with a program intended to help patients comply with the once-monthly oral dosing regimen
Merck’s ‘COVID Pill’ Shows Promise, But Mortality Benefits Will Be Hard To Prove
Early results from its novel antiviral are encouraging, but demonstrating life-saving qualities in a short window of time will be tricky.
ROI For US With FDA's Emergency Use Approval Of Cue Health's OTC At-Home COVID-19 Test
After federal agencies invested almost $5600m to ensure Cue Health could scale up production, FDA announces the self-administered test will be available OTC. it's the agency's first emergency use authorization for an at-home molecular diagnostic test available nonprescription.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: